Study to Evaluate the Safety and Efficacy of Serplulimab Plus Bevacizumab and Chemotherapy in NSCLC Patients With Brain Metastases

NCT05807893 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Non-small Cell Lung Cancer Stage II
Bevacizumab
Immunotherapy
Brain Metastases

Interventions

DRUG: Serplulimab combined with bevacizumab and first-line chemotherapy

Sponsor

Sun Yat-sen University